NASDAQ:CBMG

Delisted

Cellular Biomedicine Group Stock News

Buy CBMG

*Your capital is at risk

$19.75

+0 (+0%)

At Close: May 27, 2022

Baird Initiates Coverage On Cellular Biomedicine Gr with Outperform Rating, Announces $26 Price Target

12:00am, Thursday, 07'th Feb 2019

Avalon Globocare (AVCO) Stock: The Wolf of Wall Street?

05:54pm, Friday, 25'th Jan 2019

Low-priced biotech stocks are often targets of pump-and-dump manipulation scams or other activity designed to make money for a select few, not you (think

Week In Review: Yantai's MabPlex Raises $59 Million To Expand CDMO Services

12:00am, Sunday, 20'th Jan 2019

Cellular Biomedicine Group's AlloJoin Therapy For Knee Osteoarthritis Becomes The First Stem Cell Drug Application Approved In China For Phase II Clinical Trials

12:00am, Thursday, 17'th Jan 2019

Week In Review: China Life Science Starts Off 2019 With $425 Million In Deals

12:00am, Sunday, 13'th Jan 2019

Cabaletta Bio Closes $50M Series B Financing | FinSMEs

05:54pm, Wednesday, 09'th Jan 2019

Cabaletta Bio, a biotech company focused on the development of T cell therapies for B cell-mediated autoimmune diseases, closed a $50m Series B financing

Cellular Biomedicine Group Initiates Patient Recruitment for Clinical Trial in B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting Multiple Myeloma (MM)

12:00am, Wednesday, 09'th Jan 2019

UPDATE: Cellular Biomedicine Says Novartis Seeks To Entrust Co.'s China Unit To Perform Certain Processing, Supply, Managerial Aspects Of Certain Products In China Region

12:00am, Friday, 28'th Dec 2018

88 Biggest Movers From Yesterday

12:00am, Thursday, 08'th Nov 2018

Cellular Biomedicine Gr Q3 EPS $(0.56) Misses $(0.52) Estimate, Sales $70.431K Beat $50K Estimate

12:00am, Tuesday, 06'th Nov 2018

Earnings Preview: Cellular Biomedicine Group (CBMG) Q3 Earnings Expected to Decline

12:00am, Thursday, 01'st Nov 2018

44 Biggest Movers From Yesterday

12:00am, Friday, 12'th Oct 2018

UPDATE: Cellular Biomedicine Group To Repurchase Shares Of Its Common Stock For A Purchase Price Not To Exceed $8.4M

12:00am, Wednesday, 10'th Oct 2018

55 Biggest Movers From Yesterday

12:00am, Thursday, 04'th Oct 2018

Cellular Biomedicine Group Obtains NCI Patent License For Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology To Treat Solid Tumors

12:00am, Wednesday, 03'rd Oct 2018

Cellular Biomedicine Group Stock News

Baird Initiates Coverage On Cellular Biomedicine Gr with Outperform Rating, Announces $26 Price Target

Avalon Globocare (AVCO) Stock: The Wolf of Wall Street?

Week In Review: Yantai's MabPlex Raises $59 Million To Expand CDMO Services

Cellular Biomedicine Group's AlloJoin Therapy For Knee Osteoarthritis Becomes The First Stem Cell Drug Application Approved In China For Phase II Clinical Trials

Week In Review: China Life Science Starts Off 2019 With $425 Million In Deals

Cabaletta Bio Closes $50M Series B Financing | FinSMEs

Cellular Biomedicine Group Initiates Patient Recruitment for Clinical Trial in B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting Multiple Myeloma (MM)

UPDATE: Cellular Biomedicine Says Novartis Seeks To Entrust Co.'s China Unit To Perform Certain Processing, Supply, Managerial Aspects Of Certain Products In China Region

88 Biggest Movers From Yesterday

Cellular Biomedicine Gr Q3 EPS $(0.56) Misses $(0.52) Estimate, Sales $70.431K Beat $50K Estimate

Earnings Preview: Cellular Biomedicine Group (CBMG) Q3 Earnings Expected to Decline

44 Biggest Movers From Yesterday

UPDATE: Cellular Biomedicine Group To Repurchase Shares Of Its Common Stock For A Purchase Price Not To Exceed $8.4M

55 Biggest Movers From Yesterday

Cellular Biomedicine Group Obtains NCI Patent License For Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology To Treat Solid Tumors

Top Fintech Company